A Phase IB Multicenter, Open-label Study To Determine The Recommended Dose And Regimen Of Durvalumab (MEDI4736) Either As Monotherapy or In Combination With Pomalidomide (POM) With Or Without Low-Dose Dexamethasone (DEX) In Subjects With Relapsed And Refractory Multiple Myeloma (RRMM)

Trial Profile

A Phase IB Multicenter, Open-label Study To Determine The Recommended Dose And Regimen Of Durvalumab (MEDI4736) Either As Monotherapy or In Combination With Pomalidomide (POM) With Or Without Low-Dose Dexamethasone (DEX) In Subjects With Relapsed And Refractory Multiple Myeloma (RRMM)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Durvalumab (Primary) ; Dexamethasone; Pomalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 31 Jan 2017 Planned End Date changed from 1 Nov 2017 to 1 Aug 2018.
    • 31 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Oct 2017.
    • 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top